AzTrials
AzTrials

Rheumatoid ArthritisPhase 1/2NCT03355872

A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs

A Phase 1/2 study testing HLX01 in people with Rheumatoid Arthritis, run by Shanghai Henlius Biotech.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To compare the PK profiles of HLX01 and Rituximab in Chinese patients with moderate to severe rheumatoid arthritis. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
HLX01
Could I receive a placebo?
No, everyone receives an active treatment
How many people
194 participants
Where
No sites listed yet
Study dates
Feb 2016to Aug 2018
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female participants, between 18 and 65 years of age, who have a diagnosis of moderately to severely active RA for at least 6 months as defined by at least 6 swollen joints (66 joint count) and at least 6 tender joints (68 joint count) at Screening and Baseline (Day 1), and DAS28-CRP>3.2 at Screening. If a joint has both swollen and tender symptoms, then the joint will be included in both the swollen joints and tender joint categories.
  • Current treatment for RA:
  • Must be currently receiving and tolerating oral or parenteral MTX therapy at a dose of 10 25 mg per week for at least 12 weeks prior to Day 1. The dose should be stable for at least 4 weeks prior to Day 1. Patients must have had an inadequate response to small molecule or biologic DMARD therapy.
  • Patients must be willing to receive oral folic acid (at least 5 mg/week or as per local practice) or equivalent during the entire study (mandatory co-medication for MTX treatment).
  • Inadequate response to biologic DMARDs: anakinra and etanercept must be withdrawn at least 4 weeks prior to Day 1; tocilizumab must be withdrawn at least 12 weeks prior to Day 1; other agents must be withdrawn at least 12 weeks or 5 half-lives (whichever is longer) prior to Day 1.
  • Inadequate response to small molecule DMARDs (other than MTX): Leflunomide must be withdrawn at least 8 weeks prior to Day 1 or a minimum of 2 weeks prior to Day 1 if after 11 days of standard cholestyramine washout. Lower than 400 mg/day of oral hydroxychloroquine or lower than 250 mg/day of oral chloroquine is allowed, but the dose should be stable for at least 12 weeks prior to Day 1 until Week 24 (if hydroxychloroquine or chloroquine have been discontinued, they must have been withdrawn at least 4 weeks prior to Day 1). Other DMARDs must be withdrawn at least 4 weeks prior to Day 1.
Show all 11Show fewer
  • Tripterygium wilfordii: ongoing therapy is allowed, but the dose should be stable for at least 12 weeks prior to Day 1 until Week 24; if discontinued, T.wilfordii treatment must have been withdrawn at least 2 weeks prior to Day 1.
  • If receiving current treatment with oral corticosteroids, the dose must not exceed 10 mg/day prednisolone or equivalent. During the 4 weeks prior to Baseline (Day 1) the dose must remain stable until Week 24; if discontinued, oral corticosteroids must have been withdrawn at least 2 weeks prior to Day 1.
  • Intra-articular and parenteral corticosteroids are not permitted within 6 weeks prior to Baseline Day 1 and throughout the trial (until Week 24), with the exception of IV administration of 100 mg methylprednisolone 30 minutes prior to each infusion as this is part of the trial procedures.
  • Any concomitant non-steroidal anti-inflammatory drugs (NSAIDs) must be stable for at least 2 weeks prior to Day 1; if discontinued, NSAIDs must have been withdrawn at least 2 weeks prior to Day 1.
  • Males or females of child-bearing potential must agree to use an acceptable method of contraception for 12 months following completion or discontinuation from the trial (e.g., hormonal contraceptive, patch, intrauterine device, physical barrier).

Who cannot join

  • ACR functional Class IV or wheelchair/bed bound.
  • Primary or secondary immunodeficiency (history of, or currently active), including known history of human immunodeficiency virus infection and Positive HIV.
  • Active tuberculosis (e.g., chest X-ray images of active tuberculosis); for those who have used TNF-α antagonist or in the opinion of the investigator, QUANTIFERON®-TB GOLD will be tested and the positive patients will be excluded.
  • Congestive heart failure (Class III or IV of New York Heart Association)
  • Interstitial lung disease (except mild).
  • Known allergies to mouse protein or other antibodies.
Show all 25Show fewer
  • History of cancer including solid tumors, hematologic malignancies, and carcinoma in situ (except participants with previous resected and cured basal or squamous cell carcinoma, cervical atypical dysplasia, or in situ Grade I cervical cancer at least 1 year prior to the Screening Visit).
  • Receipt of a live/attenuated vaccine within 12 weeks prior to the Screening Visit until Week 24.
  • Any disease or treatment (including biotherapy) that may bring unacceptable risk to the subject, in the opinion of the investigator
  • Pregnant or lactating female subjects, or subjects who are planning to conceive or breastfeed during the study period or within 12 months after the last administration.
  • History of, or current, inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, pulmonary fibrosis, or Felty's syndrome, scleroderma, inflammatory myopathy, mixed connective tissue disease, or any overlap syndrome).
  • Evidence of significant uncontrolled concomitant disease such as, but not limited to, nervous system, renal, hepatic, endocrine, or gastrointestinal disorders which, in the investigator's opinion, would preclude patient participation.
  • Positive anti-HCV antibodies at screening.
  • Positive anti-TP antibodies at screening.
  • Positive HBsAg or HBcAb, or HBV DNA ≥1×103 copies/mL at screening.
  • Any active infection (except nail bed fungal infection), or any serious infections needed hospitalized or intravenous anti-infective treatment within 4 weeks before the screening visit; or oral anti-infective therapy within 2 weeks before the screening visit.
  • History of deep gap/tissue infection (e.g. fasciitis, abscess, osteomyelitis) within 52 weeks prior to the screening visit.
  • Experienced serious or opportunistic infection in the recent 2 years in the opinion of the investigator.
  • History of chronic infection (such as chronic pyelonephritis, bronchiectasis or osteomyelitis)
  • Any congenital or acquired neurological disease, vascular disease or systemic disease, especially joint pain and swelling (e.g., Parkinson's disease, cerebral palsy, diabetic neuropathy) that may affect the effects assessment of this study.
  • History of alcohol abuse, drug abuse within 52 weeks prior to the screening visit (judged by the investigator).
  • Received anti-integrin αV antibody or cell depletion therapy within 3 months or 5 half-lives (whichever is longer) prior to the screening visit.
  • Intolerant to glucocorticoid injection or has contraindication to glucocorticoid.
  • AST or ALT >2 times ULN. Or haemoglobin < 8.0 g/dL. Or absolute neutrophil count < 1.5x109/L. Or platelet count < 75x109/L.
  • Participated in any clinical study (within 12 weeks or within 5 half-lives of the study drug, whichever is longer).

About this study

To compare the PK profiles of HLX01 and Rituximab in Chinese patients with moderate to severe rheumatoid arthritis.

Being tested
HLX01
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • HLX01Drug

    Biosimilar of Rituximab

Study groups in NCT03355872
Study groupRoleWhat they receive
HLX01ExperimentalNot described
Receives: Drug: HLX01
RituximabActive comparatorNot described
Receives: Drug: HLX01

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. AUC(0-inf)

    Measured: 24weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Nov 2017
  2. Study startFeb 2016
  3. Primary completionAug 2018
  4. Study completionAug 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
194 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03355872
Sponsor's protocol ID
HLX01-RA01
Status last verified
May 2022
First submitted
22 Nov 2017
Last updated
9 May 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing HLX01 in people with Rheumatoid Arthritis, run by Shanghai Henlius Biotech.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 May 2022. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

AUC(0-inf) (time frame: 24weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03355872.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2022; AzTrials last refreshed its copy on 27 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in